BibbInstruments

BibbInstruments FCF CAGR 5Y

The FCF CAGR (5 Year) of BibbInstruments (BIBB.SL) as of Oct 24, 2026 is 5.95 %.

FCF CAGR 5Y

5.95 %

Last updated:

FCF CAGR (5 Year) of BibbInstruments is 2025 5.95 % . FCF CAGR (5 Year) of BibbInstruments was 2024 - . It decreases by % lower compared to the previous year.

The BibbInstruments FCF CAGR 5Y history

The BibbInstruments FCF CAGR 5Y history
YEARFCF CAGR 5YYoY
5.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BiBBInstruments AB generates revenue through the development and sale of diagnostic instruments for early cancer detection, primarily utilizing its EndoDrill technology platform. The company markets specific products including EndoDrill GI Upper for stomach biopsies, EndoDrill GI Lower for intestinal biopsies, EndoDrill GI Lung for lung biopsies, EndoDrill Therapy for organ displacement procedures, EndoDrill Needle for breast biopsies, and EndoDrill Model X for multiple applications. These instruments are sold to hospitals with endoscopy specialist centers and surgical wards, focusing on Scandinavian countries as their primary market. The company's portfolio targets medical professionals requiring precise diagnostic tools for deep skin tissue analysis and treatment procedures. The business model centers on selling specialized biopsy instruments that enable early cancer diagnosis in various organs. EndoDrill GI Upper, GI Lower, and GI Lung are designed for gastrointestinal and respiratory tract biopsies, while EndoDrill Therapy facilitates treatment procedures involving stents and conductors. EndoDrill Needle specifically addresses breast biopsy needs, and EndoDrill Model X serves as an independent research project covering multiple anatomical areas. All products are distributed through hospital networks specializing in endoscopy and surgery. BiBBInstruments AB's revenue streams are derived from direct sales of its diagnostic instrument portfolio to healthcare institutions. The company focuses on Scandinavian countries for distribution, targeting hospitals with specialized endoscopy centers and surgical departments. The EndoDrill technology platform underpins all products, providing a unified approach to early cancer detection and treatment procedures across different medical specialties. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

FCF CAGR (5 Year) of BibbInstruments is 5.95 % in 2025.

On Eulerpool you can find the complete historical development of FCF CAGR (5 Year) BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

The 5-year FCF CAGR shows the compound annual growth rate of free cash flow over five years.

To evaluate FCF CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF CAGR (5 Year).

FCF CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track FCF CAGR (5 Year)'s BibbInstruments historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BibbInstruments

All Key Metrics — BibbInstruments